Beneficiary 01: GSKVACSRL (GSK Vaccines S.R.L.), Siena, Italy
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
GSK is one of the world’s leading vaccine companies, involved in vaccine research, development and production. We have 14 vaccines in development and our broad portfolio of 41 vaccines prevent illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Globally, we have more than 16,000 people working to deliver more than 2 (2.3) million vaccines every day, to people in 166 countries.
joined Novartis Vaccines in 2006 as Associate Project Leader for S. pneumoniae vaccine discovery; in March 2015, Novartis non-influenza Vaccines business was acquired by the GSK group of companies. In 2010 he was appointed as Project Leader for vaccine research on S. aureus. His work on S. aureus led to a clinical trial on this vaccine and to the filing of several patents. He has published more than 40 papers in several peer-reviewed journals including PNAS, FASEB J., J. of Infectious Disease, Curr. Opinion Micr.. Furthermore, he is the editor of four scientific books and associate editor of Frontiers Microbial Immunology journal.
During his career as researcher and project leader, Dr Fabio Bagnoli has supervised teams composed of researchers and technicians as well as post docs and Ph.D students.
Beneficiary 02: UMC Utrecht (University Medical Center Utrecht), Utrecht, The Netherlands
UMCU is one of the oldest universities in the Netherlands and one of the largest in Europe. The university is rated as the best university in the Netherlands by the Shanghai Ranking of World Universities 2013. The UMC Utrecht offers a wide range of Ph.D programs. It is one of the largest university medical centers in the Netherlands and a leader in many areas of high quality (biomedical) education and research. University Medical Center Utrecht strives to achieve the highest levels in, patient care, scientific research and education.
Prof. Jos A. G. van Strijp is a full professor and Head of Experimental Microbiology at Dept. Medical Microbiology, University Medical Center Utrecht (UMCU) and has 35 years of research experience. He is also the Director of the Graduate School of Life Sciences Utrecht and the Director of the Ph.D-program and Master Program in Infection & Immunity (I&I) (180 Ph.D students); in this context he oversees all courses, evaluates progress, updates the program. He now leads a group of 30 scientists, all involved in bacterial pathogenesis. Van Strijp has published more than 140 papers in many top journals (such as Cell, Nature Immunol., J Exp Med, etc) and has supervised 35 Ph.D students and 25 Postdocs.
Partner 01: SUMC (The Leland Stanford Junior University), Stanford, USA
The Leland Stanford Junior University was founded in 1885 by California Senator Leland Stanford and his wife, Jane, in memory of their only child, Leland Jr., who died of typhoid fever at 15.
Stanford University is a private institution that was founded in 1885. It has a total undergraduate enrollment of 7,034, its setting is suburban, and the campus size is 8,180 acres. Stanford is one of the most prestigious University in the United States.
Four of Stanford University’s seven schools offer undergraduate and graduate coursework, and the remaining three serve as purely graduate schools. Graduate programs include the highly ranked School of Education, School of Engineering, Law School, School of Medicine and the top-ranked Graduate School of Business.
Manuel Amieva is Associate Professor of Paediatrics & Microbiology and Immunology at Stanford University, experienced in interactions of S. aureus with human skin. To do that, he has developed a skin equivalent model built with primary keratinocytes and fibroblasts extracted from neonatal human foreskin grow on extracellular matrix from cadaveric skin. Professor Amieva will give lectures in the First Workshop “Skin model & Vaccinology”.
Partner 02: UoS (University of Siena), Siena, Italy
The University of Siena in Tuscany, is one of the oldest and first publicly funded universities in Italy.
The department of Biotechnology, Chemistry and Pharmacy and the Plastic Surgery Unit of the Department of Medical, Surgical and Neurological Sciences are involved in the DISSEction Project for the fellow’s training activities. .
Dr. Agnese Magnani is associate Professor of inorganic chemistry. Her lab is focused on synthesis and characterisation of polymeric materials and hydrogels for biomedical applications as well as scaffolds for cell cultures, tissue engineering, and drug delivery systems. Prof. Magnani will participate in the training program of the students giving lectures on the above mentioned topics during the First and Second Workshops in “Skin model & Vaccinology” and by hosting ESR4 for 1 month.
Luca Grimaldi is associate professor of plastic surgery at the University of Siena. He will be involved in the training program giving lectures in the Workshop 1. Furthermore, ESR1 and ESR3 will have the chance to use human skin explants, for corroborating data got with the skin equivalent model.
Partner 03: ALTA (ALTA Ricerca e Sviluppo in Biotecnologie S.r.l.u.), Siena, Italy
ALTA is a service-provider company specialized in developing and managing scientific research projects financed by the European Commission and Italian Public Authorities. Advanced training programs are also a strength of ALTA. Founded in 1998 by Aldo Tagliabue, ALTA has been involved in several projects since the 5th FP. ALTA has been chosen by 39 among the top Italian scientists and is involved in the management of 18 projects funded by the EC.
ALTA provides support and consultancy services for scientists and researchers at universities, in businesses and research institutes from the idea to project implementation finding the proper strategy, building the Project Consortia and putting science in the most appropriate administrative and management framework.
Our team is a perfect blend of project managers with great knowledge of public funding rules, scientists with expertise in immunology, microbiology, pharmacology and chemistry and experts in administration, communication and events organization.
Gabriella Dessole obtained her Masters Degree in Chemistry in 2001. She worked for several years in the pharmaceutical field as Research Chemist and in the patent field as Patent Documentalist. In 2016 Gabriella joined ALTA S.r.l.u. and she is currently Grants Manager.
Back to top